Will Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Prove Temporary Given Strong Fundamentals?
Will Weakness in Edwards Lifesciences Corporation's (NYSE:EW) Stock Prove Temporary Given Strong Fundamentals?
It is hard to get excited after looking at Edwards Lifesciences' (NYSE:EW) recent performance, when its stock has declined 7.9% over the past three months. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Specifically, we decided to study Edwards Lifesciences' ROE in this article.
近三個月，愛德華生命科學（NYSE:EW）的股票下跌了7.9％，因此對其最近的表現感到興奮是困難的。但是，如果您仔細關注，您可能會得出結論，鑑於市場通常會獎勵財務狀況良好的公司，其強大的財務狀況可能意味着股票長期以來可能會看到價值提升。具體而言，在本文中，我們決定研究愛德華生命科學的roe。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
roe或股東權益回報率是評估公司如何有效地從股東那裏獲得回報的有用工具。簡而言之，它用於評估公司相對於其權益資本的盈利能力。
How Is ROE Calculated?
淨資產收益率怎麼計算？
The formula for ROE is:
roe的公式是：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤（從持續經營中獲得）÷ 股東權益
So, based on the above formula, the ROE for Edwards Lifesciences is:
愛德華生命科學的roe，根據上述公式，爲20％= 14億美元 ÷ 72億美元（基於截至2024年3月的過去十二個月）。
20% = US$1.4b ÷ US$7.2b (Based on the trailing twelve months to March 2024).
愛德華生命科學的淨利潤是14億美元。
The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.20 in profit.
“回報”指的是公司過去一年的收益。另一種思考方式是，對於每1美元的股本，公司能夠獲得0.20美元的利潤。
What Is The Relationship Between ROE And Earnings Growth?
既然我們已經確定ROE是一種有效的利潤生成標準，用於評估公司未來的盈利能力，我們現在需要評估公司“保留”爲未來增長而重新投資的利潤多少，這使我們對公司的增長潛力有了一個了解。一般而言，在其他條件相等的情況下，ROE和利潤留存高的公司，增長率比沒有這些屬性的公司要高。
So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
到目前爲止，我們已經了解了ROE是衡量公司盈利能力的一種指標。根據公司選擇重新投資或“保留”的利潤數量，我們能夠評估公司未來產生利潤的能力。一般而言，其他條件相等的情況下，具有高股東回報率和利潤保留能力的公司比不具備這些屬性的公司具有更高的增長率。
A Side By Side comparison of Edwards Lifesciences' Earnings Growth And 20% ROE
愛德華生命科學盈利增長和20％ roe的並排比較。
At first glance, Edwards Lifesciences seems to have a decent ROE. On comparing with the average industry ROE of 11% the company's ROE looks pretty remarkable. Probably as a result of this, Edwards Lifesciences was able to see a decent growth of 14% over the last five years.
初看，愛德華生命科學的roe似乎不錯。與行業平均roe 11％相比，該公司的roe看起來非常顯著。可能由於此原因，愛德華生命科學能夠在過去五年中實現14％的良好增長。
Next, on comparing with the industry net income growth, we found that Edwards Lifesciences' growth is quite high when compared to the industry average growth of 8.7% in the same period, which is great to see.
接下來，與行業淨收入增長相比較，我們發現愛德華生命科學的增長比同期行業平均增長8.7％高得多，這是非常好的。
Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you're wondering about Edwards Lifesciences''s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
盈利增長是股票估值的巨大因素。了解市場是否已將公司預期的盈利增長（或下降）定價是投資者重要的任務。這樣做，他們將了解股票是走向清澈的藍色水域還是等待沼澤水域。如果您想了解愛德華生命科學的估值，請查看我們與行業相比的市盈率測量指標。
Is Edwards Lifesciences Efficiently Re-investing Its Profits?
愛德華生命科學是否有效地重新投資其利潤？
Edwards Lifesciences doesn't pay any regular dividends, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.
愛德華生命科學不支付任何常規股息，這意味着其所有利潤都被再投入到業務中，並解釋了公司看到的相當多的盈利增長。
Conclusion
結論
On the whole, we feel that Edwards Lifesciences' performance has been quite good. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
總體而言，我們認爲愛德華生命科學的表現相當不錯。具體而言，我們喜歡該公司以高回報率重新投資其巨額利潤的做法。當然，這導致了該公司盈利的大幅增長。但是，根據目前的分析師預測，該公司的盈利增長預計將放緩。這些分析師預期是基於行業的廣泛預期還是基於公司的基本面？請單擊此處，進入我們的分析師預測頁面查看。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。